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Dear Editor, 
 
We are writing to bring serious concerns about the validity of the paper “Hematologic 
toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 
18 randomized controlled trials
1
” authored by Ran Cui and colleagues” recently 
published by the International Journal of Cancer to your attention. After careful reading, 
we firmly believe that the review uses inappropriate methods and incorrect data and 
therefore that the conclusions are misleading.  
 
We should be clear that the reason that we have been able to consider the data so 
carefully is that our group is conducting a systematic review on serious thromboembolic 
adverse events which has a very similar design (PROSPERO registration number 
CRD42014009165
2
), although our systematic review also includes RCTs in which 
panitumumab (another approved anti-EGFR monoclonal antibody) is tested as an add-on 
to standard regimens. 
 
We detail the many shortcomings of the research reported by Cui and colleagues below. 
(1) Search strategy and missing trials 
We were surprised by the small number of records (511) returned by the authors’ 
initial search, the number of RCTS identified (18) and by the small number of 
articles that were excluded on grounds of lack of data (2). In contrast our own 
search, yielded a total of 6777 records of which 45
3-5,7-48
 were RCTs. Of the 37
3-
16,19-20,22-28,30-34,36-38,40-41,43,45,47-48
 trials of cetuximab, 32
3-6,8-12,14-16,19-20,22-28,30-34,36-
38,40-41,43,45,47-48
 reported data on hematologic toxicities. 
 
 
Cui and colleagues do not report their search strategies in full, making it difficult 
to have confidence in their quality. From the information given, it would seem 
that, although there are several rigorous search filters that can be used to identify 
RCTs, none of these were used in either MEDLINE or Embase. It also seems that 
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 the Cochrane Central Register of Controlled Trials was not used. The impact of 
these choices would be to restrict the number of papers identified by the literature 
searching.  
 
As of October 31
st
, 2013, the time at which the literature search by Cui and 
colleagues was done, six of the additional sixteen RCTs that we identified were 
already published. These six trials (including over 1,700 participants) should 
therefore have been identified and added to the 18 trials they included (see Table 
1).  
 
To date, further data from more than 5,000 patients are available, as compared to 
the analysis of Cui and colleagues; around one third of these data were already 
published at the time of their search and therefore have been missed from the 
review. 
 
 
(2) Inclusion of an ineligible trial 
The authors included a trial reported by Cunningham et al.
49
 in which both 
treatment and control groups received cetuximab. This does not match their stated 
inclusion criteria and should have been excluded from the review (for the same 
reason as they did exclude 3 trials - see flow-chart)
1
.  
 
 
(3) Quality assessment 
 
The Authors assessed the quality of the evidence using the Jadad scale
50
. The use 
of this scale is explicitly discouraged by Cochrane
51
. As well as suffering from the 
generic problems of scales, it has a strong emphasis on reporting rather than 
conduct, and does not cover one of the most important potential biases in 
randomized trials, namely allocation concealment. The PRISMA statement
52
, 
which Authors declare their paper to be compliant with, describes scales that 
numerically summarise multiple components into a single number as misleading 
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 and unhelpful. In addition, the reported quality evaluation does not reflect the 
content of the articles reviewed. The Jadad Scale assigns up to two points out of a 
possible 5 score for blinding procedures
50
. Although all the studies included in the 
analysis are open label, reducing the maximum score to 3 points, four studies 
received scores higher than 3 
5,10,31,49
. 
 
 
(4) Inappropriate combination of neutropenia and leukopenia events 
The authors have combined neutropenic events with broader leukopenic events 
(which include both neutropenia and lymphocytopenia) in the analyses. This is 
both inappropriate clinically, and unnecessary. In all the trials included in this 
study, neutropenia and leukopenia adverse events are listed separately, with the 
only exception being the trial reported by Ye and colleagues
47
. Besides the 
clinical incoherence, potential double-counting and combination of overlapping 
outcomes may lead to analytical issues.  
The issue of double counting is illustrated in the trial conducted by Lynch and 
colleagues
25
, where the sum of neutropenic and leukopenic adverse events 
exceeds the denominator in the experimental arm. In their letter, Cui and 
colleagues responded to this by changing the denominator, but they did not 
provide any justification or description of the method used to calculate the new 
number.  
 
Furthermore, summing leukopenic and neutropenic events is not applied 
consistently across trials. In at least one case only leukopenic events have been 
extracted and analysed
12
.  For the articles by Rosell and colleagues
34
 it is not clear 
what has been done, as this trial, although listed in the summary table of included 
studies, does not appear in the forest plot of relative risk
1
. 
 
 
(5) Errors in data extraction/analysis 
We found several inconsistencies between the data reported in the original articles 
and the data analysed in the review: 
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- the analysis of wild type patients did not include the data presented by 
Bokemeyer
5
 and colleagues (see Figure 2 in the paper
1
); while Cui and his 
group, reviewed the article published in 2009, the results were presented in 
a more recent report
6
, which was published by Annals of Oncology in 
2011; 
 
- although data on neutropenia from the report by Rosell and colleagues
34
 
and data on anemia, from the EXPERT
45
 trial reported by Vermorken et al. 
were presented in the articles reviewed, these trials do not appear in the 
analysis of relative risk (Figure 3
1
 and Supporting information table s1 
respectively); moreover data on anemia were available for the OPUS trial 
from the more recent report
6
 published in 2011; 
 
- in one case grade 4 adverse events were counted twice (Vermorken et al
45
, 
see Table 2), while, in another, those of grade 3 were neglected (Rosell et 
al
34
, see Table 3); 
 
- In at least one case, the proportion of adverse events, expressed as a 
percentage, was used as the actual number of events, without being 
converted
37
. 
 
 
Hematologic toxicities are one of the main concerns in patients exposed to cancer 
treatments. Considering the relevance of synthesized evidence in clinical practice as well 
as in regulatory decision-making processes, we strongly believe that the publication of 
misleading analyses, based on poor methods and incorrect data, in an important journal 
may have important consequences on public health and future research. 
 
We believe that the extent of the errors in the Cui et al. article are substantial and that it 
may affect not only the estimates but even the direction of the effect. Readers of the 
journal and article need to be made aware of its potential to mislead. 
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Table 1. Published RCTs of anti-EGFR monoclonal antibodies 
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 Table 2. Neutropenia and Leukopenia AEs in the RCTs included by Cui et al. as reported 
in the original articles. 
 
Leukopenia AEs as reported in RCTs Neutropenia AEs as reported in RCTs Neutropenia  AEs in  Cui et al.
Cetuximab Arm Control Arm Cetuximab Arm Control Arm Cetuximab Arm Control Arm
Study ID Events Total Pts Events Total Pts Events Total Pts Events Total Pts Events Total Pts Events Total Pts
Alberts (3) 156 1273 132 1261 156 1273 132 1261
Baselga (4) 11 114 3 57 11 114 3 57
Bokemeyer* (5,6) 12 170 10 168 51 170 57 168 63 170 67 168
Butts (10) 31 64 32 66 31 64 32 66
Cascinu (11) 10 42 6 42 10 42 6 42
Crosby (12) 14 129 21 129 15 129 24 129 14 129 21 129
Govindan (16) 25 53 21 50 25 53 21 50
Lorenzen (24) 7 32 4 30 7 32 4 30
Lynch (25) 139 325 97 320 198 325 177 320 337 634 274 632
Maughan (27) 101 815 107 815 101 815 107 815
Philip (30) 40 361 50 355 84 361 85 355 124 361 135 355
Pirker (31) 139 548 109 562 289 548 289 562 428 548 398 562
Rosell° (34) 21 42 16 43 35 42 23 43
Sobrero (37) 196 617 151 595 196 638 151 629
Van Cutsem (41) 43 600 32 602 169 600 150 602 212 600 182 602
Vermorken (45) 19 219 19 215 49 219 50 215 81 219 92 215
Ye^ (47) 8 70 6 68 8 70 6 68
Cunningham§ (49) Cetuximab Cetuximab 20 212 0 115 20 212 0 115
*2009 instead of 2011 (no data on anemia)
°does not appear in any forrest plot
^Ye et al. reported neutropenia/Leukopenia as one outcome
§Ineligible 
Leukopenia only 
Unclear
safety population instead of actually tested
grade 3/4 + grade 4
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 Table 3. Anemia AEs in the RCTs included by Ran Cui et al. as reported in the original 
articles and main mistakes in data extraction 
   
Anemia AEs as reported in RCTs Anemia AEs in Ran Cui et al.
Cetuximab Arm Control Arm Cetuximab Arm Control Arm
Study ID Events Total Pts Events Total Pts Events Total Pts Events Total Pts
  
Bokemeyer* (5,6) 7 170 4 168
Butts (10) 17 64 13 66 17 64 13 66
Cascinu (11) 0 42 3 42 0 42 3 42
Crosby (12) 3 129 3 129 3 129 3 129
Govindan (16) 7 53 9 50 7 53 9 50
Lorenzen (24) 2 32 0 30 2 32 0 30
Lynch (25) 17 325 15 320 17 325 15 320
Maughan (27) 38 815 13 815 38 815 13 815
Philip (30) 35 361 22 355 35 361 22 355
Pirker (31) 76 548 94 562 76 548 94 562
Rosell (34) 6 42 6 43 0 42 1 43
Sobrero (37) 16 618 19 596 16 638 19 629
Vermorken* (45) 29 219 41 215      
Cunningham° (49) Cetuximab Cetuximab 10 212 3 115   
*not found in forrest plots
°Ineligible
grade 4 only (not converted from %)
safety population instead of actually tested
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